Unternehmensübersicht
SciSparc Ltd. operates as a clinical-stage pharmaceutical entity dedicated to the development of novel therapeutics derived from cannabinoid compounds. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry where innovation in drug discovery is paramount for addressing unmet medical needs. In terms of operational scale, SciSparc Ltd. reports a market capitalization of $1.93M and generates annual revenue of $1.31M, while maintaining a very lean workforce consisting of only two employees. These valuation and revenue figures indicate that the company is a micro-cap entity with a minimal operational footprint, suggesting that its financial resources are likely concentrated entirely on its core research and development programs rather than infrastructure or sales overhead. The disparity between its modest market cap and its specific focus on developing SCI-110 for conditions such as Tourette syndrome, Alzheimer's disease, and agitation, alongside SCI-210 for autism spectrum disorder and status epilepticus, highlights its strategic positioning as a high-risk, high-potential developmental stage company.
Finanzielle Gesundheit
The company's financial performance for the trailing twelve months shows a revenue of $1.31M, yet this income is accompanied by a significant net income loss of $-6,480,000 and an EBITDA of $-7,029,000. The substantial gap between the positive revenue of $1.31M and the deeply negative net income reveals an aggressive cost structure typical of clinical-stage biotechnology firms, where research, development, and regulatory compliance costs far exceed current sales revenue. Regarding liquidity and cash management, the free cash flow is listed as N/A, which implies that the company is currently in a capital-intensive phase where cash reserves are being depleted to fund operations rather than generating positive cash flow. The margin analysis presents a complex picture with a gross margin of 38.7%, indicating that the cost of goods sold is controlled relative to revenue, while the operating margin stands at -569.5% and the profit margin is 0.0%, reflecting the heavy overhead and R&D expenses that have not yet been offset by profitability. On the balance sheet side, the company holds $0 in debt, creating a scenario where total cash versus total debt is effectively a comparison of available reserves against zero obligations, although specific cash figures are not disclosed in the available data. The absence of a debt-to-equity ratio due to the N/A classification underscores a capital structure devoid of leverage, relying solely on equity financing. Furthermore, the current ratio is listed as N/A, preventing a direct assessment of short-term liquidity ratios, while the return on equity is a staggering -1281.5% and return on assets is N/A, metrics that collectively reveal the immense dilution of shareholder value and the inability to generate returns on the asset base at this developmental stage.
Bewertungsanalyse
SciSparc Ltd. presents a valuation profile heavily skewed by its lack of profitability, evidenced by a trailing P/E ratio of 0.00 and a forward P/E of N/A. The absence of a forward P/E and the zero trailing P/E imply that traditional earnings-based valuation models are inapplicable, signaling that the market values the company based on future potential rather than current or expected earnings trajectory. The price-to-book ratio is recorded at 0.02, which indicates that the market is valuing the company at a fraction of its net book value, suggesting a significant discount often applied to distressed or pre-revenue biotechnology stocks. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.48 and an EV/EBITDA of N/A, suggesting that investors are pricing the stock primarily on its revenue generation capabilities rather than earnings or enterprise value multiples. In terms of trading range volatility, the stock has experienced a wide spread between a 52-week high of $94.50 and a 52-week low of $3.32. Given the current market cap of $1.93M, the stock is trading significantly below its 52-week high, reflecting the severe underperformance relative to its recent peak, while the beta of 1.33 indicates that the stock's price volatility is expected to be 33% higher than the broader market movements.
Growth & Income
The financial data indicates that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, reflecting the company's early stage where historical comparison periods may not be available or material. Since the earnings are negative at $-6,480,000, the concept of earnings growing faster or slower than revenue is not applicable in the traditional sense, as the company is focused on capitalizing on its drug development programs for Tourette syndrome and Alzheimer's disease rather than expanding profit margins. Regarding income distribution, the company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available resources are being reinvested into the company's operational needs and research initiatives. Consequently, the overall growth and income profile for SciSparc Ltd. is characterized by a complete reinvestment strategy aimed at advancing its clinical-stage pharmaceutical pipeline, with no current return to shareholders via dividends.